Increased serum xylosyltransferase activity in patients with liver fibrosis

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 123-126

  Kuhn, Joachim ^a   Gressner, Olav A ^b   Götting, Christian ^a   Gressner, Axel M ^b   Kleesiek, Knut ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Glycosaminoglycans; Hepatitis C virus; Liver fibrosis; Proteoglycans; Xylosyltransferase

Indexed keywords

PROTEOGLYCAN; TRANSFERASE; UNCLASSIFIED DRUG; XYLOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCORING SYSTEM; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C; HOMEOSTASIS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PENTOSYLTRANSFERASES; PROTEOGLYCANS; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 70349828992     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.09.013     Document Type: Article

References (38)

1. Schuppan D., Ruehl M., Somasundaram R., and Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21 (2001) 351-372
2. Gressner A.M., Krull N., and Bachem M.G. Regulation of proteoglycan expression in fibrotic liver and cultured fat-storing cells. Pathol Res Pract 190 (1994) 864-882
3. Afdhal N.H., and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 (2004) 1160-1174
4. Gressner O.A., Weiskirchen R., and Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 381 (2007) 107-113
5. Gressner O.A., Rizk M.S., Kovalenko E., Weiskirchen R., and Gressner A.M. Changing the pathogenetic roadmap of liver fibrosis? Where did it start - where will it go?. J Gastroenterol Hepatol 23 (2008) 1024-1035
6. Gressner A.M., and Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10 (2006) 76-99
7. Gressner O.A., and Gressner A.M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liv Int 28 (2008) 1065-1079
8. Roberts A.B., Tian F., DaCosta Byfield S., et al. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17 (2006) 19-21
9. Robertson H., Kirby J.A., Yip W.W., Jones D.E., and Burt A.D. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 45 (2007) 977-981
10. Zeisberg M., Yang C., Martino M., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007) 23337-23347
11. Kaimori A., Potter J., Kaimori J., Wang C., Mezey E., and Koteish A. TGF-beta 1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in-vitro. J Biol Chem 282 (2007) 22089-22101
12. Quan T.E., Cowper S.E., and Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8 (2006) 145-150
13. Russo F.P., Alison M.R., Bigger B.W., et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130 (2006) 1807-1821
14. Forbes S.J., Russo F.P., Rey V., et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126 (2004) 955-963
15. Gressner O.A., Weiskirchen R., and Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6 (2007) 7
16. Iozzo R.V. Matrix: proteoglycans: from molecular design to cellular function. Ann Rev Biochem 67 (1998) 609-652
17. Esko J.D., and Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Ann Rev Biochem 71 (2002) 435-471
18. Condac E., Silasi-Mansat R., Kosanke S., et al. Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme of glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 104 (2007) 9416-9421
19. Senoo H., Imai K., Matano Y., and Sato M. Molecular mechanisms in the reversible regulation of morphology, proliferation, and collagen mechanism in hepatic stellate cells by the three-dimensional structure of the extracellular matrix. J Gastroenterol Hepatol 13 (1998) 19-32
20. Kovalszky I., Nagy P., Szende B., et al. Experimental and human liver fibrogenesis. Scand J Gastroenterol Suppl 228 (1998) 51-55
21. Bashey R.I., Millan A., and Jimenez S.A. Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture. Arthritis Rheum 27 (1984) 1040-1045
22. Akimoto S., Hayashi H., and Ishikawa H. Disaccharide analysis of the skin glycosaminoglycans in systemic sclerosis. Br J Dermatol 126 (1992) 29-34
23. Götting C., Sollberg S., Kuhn J., et al. Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. J Invest Dermatol 112 (1999) 919-924
24. Schöttler M., Müller S., Schön S., et al. Serum xylosyltransferase 1 activity, the new biochemical fibrosis marker, is not affected by renal insufficiency. Clin Biochem 38 (2005) 486-488
25. Götting C., Kuhn J., Sollberg S., et al. Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis. Acta Derm Venereol 80 (2000) 60-61
26. Götting C., Hendig D., Adam A., et al. Elevated xylosyltransferase 1 activities in pseudoxanthoma elasticum (PXE) patients as a marker of stimulated proteoglycan biosynthesis. J Mol Med 83 (2005) 984-992
27. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
28. Kuhn J., Prante C., Schön S., Götting G., and Kleesiek K. Measurement of fibrosis marker xylosyltransferase 1 activity by HPLC electrospray ionization tandem mass spectrometry. Clin Chem 52 (2006) 2243-2249
29. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
30. Zvibel I., Halfon P., Fishman S., et al. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liv Int 29 (2009) 208-212
31. Gressner A.M., Yagmur E., Lahme B., Gressner O., and Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 52 (2006) 1815-1817
32. Schäfer S., Zerbe O., and Gressner A.M. The synthesis of proteoglycans in fat storing cells of rat liver. Hepatology 7 (1987) 680-687
33. Gressner A.M. Activation of proteoglycan synthesis in injured liver - a brief review of molecular and cellular aspects. Eur J Clin Chem Clin Biochem 32 (1994) 225-237
34. Gressner A.M. Time-related distribution profiles of sulfated glycosaminoglycans in cells, cell surfaces and media of cultured rat liver fat storing cells. Proc Soc Exp Biol Med 196 (1991) 307-315
35. Kähnert H., Paddenberg R., and Kleesiek K. Simultaneous secretion of xylosyltransferase and chondroitin sulfate proteoglycans in chondrocyte culture. Eur J Clin Chem Clin Biochem 29 (1991) 624-625
36. Lebensztejn D.M., Skiba E., Werpachowska I., Sobaniec-Lotowska M.E., and Kaczmarski M. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B. Adv Med Sci 52 (2007) 120-124
37. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004) 1704-1713
38. Götting C., Kuhn J., and Kleesiek K. Human xylosyltransferases in health and disease. Cell Mol Life Sci 64 (2007) 1498-1517